TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04719273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)
Description: Immunohistochemistry (IHC):Integral : Tissue

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Progesterone Receptor Positive ( PGR Positive; PR Positive)
Description: Immunohistochemistry (IHC)
Study: NCT06637904

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TriVerity Test
Description: Participants in the post-phase of the study will have a 2.5 ml whole blood draw obtained via venipuncture into a PAXgene® Blood RNA tube. Blood samples will be processed using the TriVerity Cartridge on the Myrna Instrument located in the ED.
Study: NCT06556394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAG-17
Description: RAG-17 is a therapeutic small interfering RNA (siRNA).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via intrathecal injection
Study: NCT05661669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo will be a 0.9% saline solution administered over 40 minutes.
Study: NCT06406595

Intervention type: OTHER
Intervention: Observation
Description: This study is observational, therefore, there is no intervention included.
Study: NCT06252493

Intervention type: DRUG
Intervention: Radiotracer Injection
Description: Injection of Gallium-68 labeled collagen binding probe 8 (\[68Ga\]CBP8):~All subjects will undergo placement of an intravenous catheter (IV). The catheter will be flushed post-injection of \[68Ga\]CBP8 with 0.9% saline solution.~The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used as needed to enable the patient to comfortably maintain his/her position throughout the scan; Up to 15 mCi of \[68Ga\]CBP8 will be administered. The injected dose and the time of injection will be recorded;~Post scan:~The catheter will be removed. The subject will be asked to void again immediately after the scan and he/she will be counseled on the importance of continuing to drink fluids for several more hours in order to increase urine flow rate and minimize the radiation dose to the bladder wall.

Intervention type: DRUG
Intervention: Contrast Media, Magnetic Resonance
Description: Dotarem 20ml will be injected during acquisition of contrast enhanced T1weighted fat saturated sequences, in keeping with standard of care MR enterography.
Study: NCT04815720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pepinemab + pembrolizumab
Description: The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
Study: NCT06493422

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reaching Movements
Description: participants will perform a perceptual decision making task while moving their hand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reaching Movements
Description: participants will perform a perceptual decision making task while moving their hand.
Study: NCT05081609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
Study: NCT06252493

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: All subjects will undergo placement of an intravenous catheter (IV). Through the same catheter, 10 mL of venous blood will be collected to evaluate blood markers for fibrostenosis.

Intervention type: DRUG
Intervention: Glucagon
Description: Glucagon will be injected into the subject's indwelling i.v. catheter (0.3-0.5 mg) before imaging acquisition; or intramuscularly (1-2 mg) prior to imaging the abdomen and pelvis. A second administration of IV glucagon (0.3-0.5mg) may take place during image acquisition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: MR and PET images of the abdomen and pelvis will be acquired using the Siemens 3 Tesla Biograph mMR scanner. Multiple anatomical and functional imaging sequences may be run to assess specific image quality measures in addition to those used for anatomical diagnosis. Among the sequences, patients will undergo a full set of standard of care MR enterography sequences to ensure they get at least same quality of study and of clinical information they would gain from a clinical study. Certain MR sequences scans may be repeated after varying a limited range of pulse sequence parameters to assess their effect on the image contrast, image artifacts and signal to noise ratio.

Intervention type: DRUG
Intervention: Oral contrast media application
Description: Patients will be invited to drink as much as possible of an oral contrast solution consisting of a mixture of 1500-2000 ml of dilute barium or sorbitol (VoLumen or Breeza) and water. Breeza, and in the past VoLumen, is routine clinical practice at MGH. The solution comes already prepared in bottles, so there is no need to dilute or prepare. The investigators will just hand the bottle to the patient and will ask the patient to start drinking \~1 hour before the scan. By routine practice at MGH, the investigators give 3-4 bottles of Breeza, about 1500-2000ml.
Study: NCT06097923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active fluid management with BIA monitoring
Description: The participants in active fluid management with BIA monitoring arm received fluid supplementation targeting specific range of ECW ratio by BIA (0.390-0.406). If a patient with dehydrated status indicated by the ECW ratio was less than 0.390, a bolus infusion was performed using 250ml of crystalloid fluid (PlasmaLyte). If a patient with overhydrated status indicated by the ECW ratio was more than 0.406, 10mg of furosemide was administered. Changes in the ECW ratio were measured at one hour after initial intervention for fluid adjustment, and these processes continued until the ECW ratio was within the normal range (0.390-0.406).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional fluid management without BIA monitoring
Description: The participants in conventional fluid management without BIA monitoring arm underwent conventional fluid management without specific targets of ECW ratio by BIA.
Study: NCT06547138

Intervention type: DEVICE
Intervention: Prophylactic mesh
Description: Prevention of incisional hernia after a prophylactic mesh in high-risk patients
Study: NCT04632992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Description: PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
Study: NCT04519801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) therapy
Description: BFR therapy beginning after first MD follow up appointment after ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard REHAB
Description: Standard post-operative rehabilitation regimen (REHAB) beginning after first MD follow up appointment ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard REHAB
Description: Standard post-operative rehabilitation regimen (REHAB) beginning after first MD follow up appointment ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion
Study: NCT05478460

Intervention type: OTHER
Intervention: Hookwire localization
Description: Patients were performed CT -guided hook wire localization(20G×120mm, PAJUNK medizintechnologie, Geisingen in Germany). patients were placed on a CT table in a suitable position(supine, prone, lateral) to obtain the shortest needle insertion route for their initial CT scan. Local anesthesia of the skin and planned puncture tract was performed using 10ml Lidocaine 1%. Next, the needle was inserted into or near the pulmonary nodule.
Study: NCT04710784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual health information
Description: We will provide participants with sexual health information, that is basic, accurate, and directly contributes to health-promoting decisions and behavior, once a week at the beginning of the study.
Study: NCT04632992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Description: PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
Study: NCT04710784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-TEST branded HIVST package
Description: The I-TEST branded HIVST package will include HIV self-testing (HIVST) kits, referral coupons, condoms, female or male hygiene products, and instructions on how to use the I-TEST photo verification App or USSD (Unstructured Supplementary Service Data) system to verify the HIVST results. Study participants will be referred to a youth-friendly health clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment and PrEP referral.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up testing and clinic assessments
Description: Information to encourage routine retesting for HIV every 6 months and linkage to the youth-friendly clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment, and PrEP referral. Additionally, follow-up surveys will be administered to assess HIV testing, sexual behavior history, youth participation experience, and other related outcomes will be collected from enrolled participants.
Study: NCT04632992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigator's Choice of Chemotherapy
Description: Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigator's Choice of Chemotherapy
Description: Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
Study: NCT06525818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tube weaning therapy intervention
Description: Participants in the intervention group will be invited to weekly virtual group therapy mealtime sessions with the Speech-Language Pathologist and other participants in the intervention group. Additionally, families will engage in individual virtual therapy sessions at least biweekly focused on individualized goals informed by the expertise of the study team and published expert programs. Therapies intervention group participants are already receiving or who begin to receive during the study period will not be stopped during this intervention. The Speech Therapist and Occupational Therapist will be utilized as needed for the child's individualized care plan. They will consult with the registered dietitian and Developmental and Behavioral Pediatrician as needed.

Intervention type: OTHER
Group type: OTHER
Intervention: Feeding Group
Description: All participants in the control group will be invited to a weekly virtual group therapy mealtime session with other enrolled control group participants and a speech therapist who is not involved with the intervention. During this informal session, families will have the opportunity to meet other children with feeding tubes and their parents. The investigators will assess level of engagement (frequency of participation) and parental experience at interval assessments. Therapies research participants are already receiving or who begin to receive during the study period (early intervention community therapies, center-based therapies) will not be stopped during this intervention. Data will be collected on the frequency of these standard of care therapies. The assessments used for the control group will be the same assessments as the intervention group and will include the Speech Therapy Assessment; Occupational Therapy Assessment; and Pediatric Eating Assessment Toll.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding Group
Description: All participants in the control group will be invited to a weekly virtual group therapy mealtime session with other enrolled control group participants and a speech therapist who is not involved with the intervention. During this informal session, families will have the opportunity to meet other children with feeding tubes and their parents. The investigators will assess level of engagement (frequency of participation) and parental experience at interval assessments. Therapies research participants are already receiving or who begin to receive during the study period (early intervention community therapies, center-based therapies) will not be stopped during this intervention. Data will be collected on the frequency of these standard of care therapies. The assessments used for the control group will be the same assessments as the intervention group and will include the Speech Therapy Assessment; Occupational Therapy Assessment; and Pediatric Eating Assessment Toll.
Study: NCT05823753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The CBD product to be used in this study is Epidiolex (Jazz Pharmaceuticals/Greenwich), a plant-derived, highly purified CBD oral solution that is FDA approved for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.~Doses will be 300 mg/d or 900 mg/d according to participants' assigned condition. Participants will receive CBD or placebo oral solution twice daily (evenly split doses at morning and evening meals) for three days (to achieve steady state) following the baseline assessment (day 0), and in the morning of day 4 (before the post-test).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The CBD product to be used in this study is Epidiolex (Jazz Pharmaceuticals/Greenwich), a plant-derived, highly purified CBD oral solution that is FDA approved for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.~Doses will be 300 mg/d or 900 mg/d according to participants' assigned condition. Participants will receive CBD or placebo oral solution twice daily (evenly split doses at morning and evening meals) for three days (to achieve steady state) following the baseline assessment (day 0), and in the morning of day 4 (before the post-test).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution (excipients only, also by Jazz Pharmaceuticals/Greenwich).
Study: NCT06412666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aficamten
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT06651827

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dentin sensitivity was measured using the Yeaple Probe and air stimulation tests before and after treatment
Description: Dentin sensitivity was measured using the Yeaple Probe and air stimulation tests before and after treatment. The effectiveness of the treatment was assessed at baseline, 30 minutes, 1 week, and 1 month post-treatment using the Visual Analog Scale (VAS) and Yeaple Probe scores.
Study: NCT06316232

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STIM ON plus
Description: increase of intensity of stimulation of 0.5 mA bilaterally

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STIM ON plus
Description: increase of intensity of stimulation of 0.5 mA bilaterally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MED ON plus
Description: administration of a 2x levodopa morning dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MED ON plus
Description: administration of a 2x levodopa morning dose
Study: NCT06249737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Each participan will train the kinematic control of each degree of freedom, according to each arm, playing a videogame using an inertial sensor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Each participan will train the kinematic control of each degree of freedom, according to each arm, playing a videogame using an inertial sensor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Each participan will train the kinematic control of each degree of freedom, according to each arm, playing a videogame using an inertial sensor.
Study: NCT06663540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise & Abacus
Description: Features two main interventions: physical exercise sessions and abacus training activities.~Physical Exercise Sessions aim to enhance fitness and cognitive function through activities like aerobic exercises and team sports. Research indicates that regular physical activity can improve memory, attention, and problem-solving skills essential for academic success.~Abacus Training Activities focus on developing mathematical skills and cognitive abilities. Children learn to manipulate the abacus for calculations, which enhances numerical understanding and memory retention, positively impacting academic performance.~The program's innovative dual approach suggests that integrating physical and cognitive training can lead to greater improvements in academic performance and emotional resilience than either intervention alone.
Study: NCT06664996

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT)
Description: SBRT will be administered on days 1, 3, and 5 at a dose of 8 Gy per fraction, totaling 3 fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab (approved)
Description: patients will receive a first dose of sintilimab at 200 mg on day 1, followed by a second dose of 200 mg on day 22 (week 4, ±3 days).
Study: NCT06665321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based psychodynamic therapy (IPDT)
Description: The intervention is 9 week long with weekly modules that the participants work with while receiving weekly support from an assigned therapist.
Study: NCT06607588

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: Not applicable- observational study